公开(公告)号：EP1188747A4

公开(公告)日：2002-10-09

申请号：EP00927844

申请日：2000-05-22

申请人： MITSUBISHI PHARMA CORP

发明人： NISHIYAMA AKIRA ,  BOUGAUCHI MASAHIRO ,  KUROITA TAKANOBU ,  MINOGUCHI MASANORI ,  MORIO YASUNORI ,  KANZAKI KOUJI

IPC分类号： A61P1/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/24 ,  A61P43/00 ,  C07D209/42 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D491/10 ,  C07D491/107 ,  A61K31/445 ,  C07D207/36 ,  C07D233/96 ,  C07D263/22 ,  C07D307/33 ,  C07D307/46

CPC分类号： C07D413/14 ,  C07D209/42 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D491/10

摘要： Phenoxypropylamine compounds represented by general formula (I), optically active isomers thereof or pharmaceutically acceptable salts thereof and hydrates of the same which have an affinity selectively for 5-HT1A receptor, simultaneously show an antagonistic activity, and inhibit the reuptake of 5-HT, thereby being usable as antidepressant agents quickly achieving an antidepressant effect wherein each symbol is as defined in the description.

摘要翻译： 通式（I）表示的苯氧基丙胺化合物，其光学活性异构体或其药学上可接受的盐及其水合物对5-HT1A受体具有选择性的亲和性同时显示出拮抗活性，并抑制5-HT的再摄取， 从而可用作抗抑郁剂，迅速达到抗抑郁作用，其中每个符号如说明书中所定义。

公开(公告)号：EP1389616A4

公开(公告)日：2004-10-06

申请号：EP02722878

申请日：2002-04-26

申请人： MITSUBISHI PHARMA CORP

发明人： KIUCHI MASATOSHI ,  KUROITA TAKANOBU ,  TOMOZANE HIDEO ,  TAKEDA SHUUZOU ,  TANAKA YOSHIHITO ,  HIGASHI HIDEMITSU ,  KUWAHARA SHIGEKI

IPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/55 ,  A61P1/04 ,  A61P11/06 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D491/10 ,  C07D491/113 ,  A61P9/10

CPC分类号： C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/55 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D491/10

摘要： A compound which has a therapeutic effect based on chemokine inhibitory activity and is satisfactory as a medicine for oral administration. The compound is a benzylpiperidine derivative represented by the following formula (1), which was found to have chemokine inhibitory activity. The compound can have enhanced chemokine inhibitory activity and heightened stability in the blood. (1) [In the formula, the symbols are the same as defined in the description.]

摘要翻译： 具有基于趋化因子抑制活性的治疗效果的化合物，作为口服给药用药是令人满意的。 该化合物是由下式（1）表示的苄基哌啶衍生物，发现其具有趋化因子抑制活性。 该化合物可以增强趋化因子抑制活性并提高血液中的稳定性。 （1）[在该公式中，符号与描述中定义的相同。]

公开(公告)号：EP0885883A4

公开(公告)日：2002-10-16

申请号：EP97903647

申请日：1997-03-03

申请人： MITSUBISHI PHARMA CORP

发明人： TANAKA HIROSHI ,  KUROITA TAKANOBU ,  TOGO YOSHIFUMI ,  ISHIBUCHI SEIGO ,  FUJIO MASAKAZU ,  FUTAMURA TAKASHI

IPC分类号： C07D209/14 ,  C07D231/54 ,  C07D231/56 ,  C07D261/20 ,  C07D401/04 ,  C07D401/06 ,  C07D413/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14

CPC分类号： C07D413/06 ,  C07D209/14 ,  C07D231/54 ,  C07D231/56 ,  C07D261/20 ,  C07D401/04 ,  C07D401/06 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

摘要： Fused heterocyclic compounds represented by general formula (I), wherein each symbol is as defined in the description, optical isomers thereof, or pharmaceutically acceptable salts thereof; pharmaceutical compositions containing the compounds of formula (I), the optical isomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable additives; and medicines containing the compounds of formula (I), the optical isomers thereof, or the pharmaceutically acceptable salts thereof. These compounds are useful antipsychotic agents efficacious against not only positive symptoms centering on the hallucination, delusion and the like peculiar to the acute stage of schizophrenia, but also negative symptoms such as emotional torpidity, abulia and autism. They are also expected as highly safe antipsychotic agents reduced in the side effects, such as extrapyramidal symptoms or abnormal internal secretion, observed in the case of administration of conventional antipsychotic agents having D2 receptor blocking effects. Thus these compounds can be used as remedies for diseases including schizophrenia.